by lorenzgerber | May 6, 2024 | Events
If you are headed to BioCentury Inc.’s BioEquity Europe Conference and are interested in learning how ImmunoScape is working toward the development of TCR-based therapies against solid tumors, send us a message. Our Co-founder and VP of Innovation Michael...
by lorenzgerber | Apr 22, 2024 | Events
Next-gen TCR-based therapies against solid tumors have the power to disrupt and transform the development, delivery, and efficacy for cancer patients. Dan Macleod, ImmunoScape’s SVP of Discovery, will be an expert speaker at this year’s TCR-based Therapies for Solid...
by lorenzgerber | Mar 26, 2024 | Events
SAN DIEGO & SINGAPORE–(BUSINESS WIRE)–ImmunoScape, a biotechnology company focused on next-generation T Cell receptor (TCR)-based immunotherapies, today announced that three abstracts have been accepted for poster presentations at the 2024 American...
by lorenzgerber | Mar 1, 2024 | Events
ImmunoScape Leadership to Present at Upcoming Industry Conferences CEO Choon-Peng Ng and Vice President of Innovation, Michael Fehlings, Ph.D., will discuss Asia’s role in the “golden age” of biotech and AI in therapeutics SAN DIEGO, Calif., and Singapore – March 1,...
by lorenzgerber | Jan 5, 2024 | News
2023 was an exciting year at ImmunoScape, featuring transformative technical progress, new partnerships, expert additions to our leadership team and more. Read our latest newsletter for a look back at the highlights as well as a look ahead at what’s on the way for...
by lorenzgerber | Dec 21, 2023 | News
The collaboration seeks to produce novel off-the-shelf TCR-based bispecific molecules designed to overcome current limitations in cell therapy approaches against solid tumors SAN DIEGO, Calif., and Singapore – December 21, 2023 – ImmunoScape, a biotechnology...
by lorenzgerber | Dec 20, 2023 | News
MiNK Therapeutics combines its unique, proprietary library of T-cell antigens with ImmunoScape’s cutting-edge platform for rapid discovery of novel T-cell receptors Therapeutic development to focus on novel cell therapies as well as bispecific immune cell...
by lorenzgerber | Dec 19, 2023 | News
Therapeutics for solid tumors remain in a nascent corner of cancer research despite representing 90% of all cancers in adults. Thirty years after the first Chimeric Antigen Receptor was reported, CAR-T cell therapies have seen significant breakthroughs managing liquid...
by lorenzgerber | Dec 19, 2023 | Events
The ImmunoScape team is heading to the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco in a few weeks. Our CEO Choon-Peng (Choon) Ng, our Vice President, Discovery Dan MacLeod, and our Senior Director, Business Development Christopher Alfonso will be in...
by lorenzgerber | Dec 12, 2023 | News
ImmunoScape Appoints Systems Immunology and Computational Biology Expert Dr. John Tsang to its Scientific Advisory Board Expertise from award-winning computational biologist, human immunologist and engineer with experience from Yale, NIH, and NIAID will help advance...